Ampio announces positive results from SPRING study
Ampio Pharmaceuticals announced positive results from the eight week extension of the twelve week SPRING study of Ampion for the treatment of osteoarthritis of the knee, or OAK. In the Spring trial of 329 patients, statistically significant achievement of primary and key secondary endpoints following a single intra-articular injection into the knee of either 4 or 10 ml of Ampion versus the Saline vehicle control were demonstrated at 12 weeks as previously reported:
